#1 Clinical Trials Search in Europe

Decitabine

Decitabine, also known by its brand name Dacogen, is a drug being studied in various clinical trials for the treatment of blood cancers like myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other myeloid malignancies. This article summarizes key information from several clinical trials investigating different aspects of decitabine’s use, including dosing schedules, routes of administration, and potential new applications.

Table of Contents

What is Decitabine?

Decitabine, also known by the brand name Dacogen, is a medication used to treat certain blood disorders and cancers[1][3]. It belongs to a class of drugs called hypomethylating agents, which work by affecting how genes are expressed in cells[3].

What Conditions Does Decitabine Treat?

Decitabine is primarily used to treat the following conditions:

  • Myelodysplastic Syndrome (MDS): A group of blood disorders where the bone marrow doesn’t produce enough healthy blood cells[3][5]
  • Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer that affects certain white blood cells[1][3]
  • Acute Myeloid Leukemia (AML): A fast-growing cancer of the blood and bone marrow[2][8]

In some cases, decitabine is being studied for use in other conditions, such as certain types of solid tumors like pancreatic cancer[6].

How Does Decitabine Work?

Decitabine works by affecting the way genes are used in cells. Specifically, it blocks a process called DNA methylation, which can sometimes cause genes to be turned off when they shouldn’t be[3]. By interfering with this process, decitabine can help:

  • Reactivate genes that control normal cell growth and development
  • Promote the production of healthy blood cells
  • Slow down or stop the growth of cancer cells

How is Decitabine Administered?

Decitabine is typically given in one of two ways:

  1. Intravenous (IV) infusion: The drug is given directly into a vein over a period of time, usually 1-3 hours[1][3]
  2. Oral tablet: A newer form of decitabine (combined with another drug called cedazuridine) can be taken by mouth[8]

The method of administration depends on the specific condition being treated and the treatment plan determined by your doctor.

Dosage and Treatment Schedules

The dosage and schedule for decitabine can vary depending on the condition being treated and the individual patient. Some common treatment schedules include:

  • 20 mg/m² given intravenously over 1 hour, once daily for 5 days, repeated every 4 weeks[1]
  • 15 mg/m² given intravenously over 3 hours, three times a day for 3 consecutive days, repeated every 6 weeks[3]
  • For the oral form (ASTX727), one tablet containing 35 mg decitabine and 100 mg cedazuridine, taken once daily for 5 days, repeated every 4 weeks[8]

Your doctor will determine the best dosage and schedule for your specific situation.

Potential Side Effects

Like all medications, decitabine can cause side effects. Some of the most common side effects include:

  • Fatigue
  • Nausea and vomiting
  • Decreased blood cell counts (which can lead to increased risk of infection, bleeding, or anemia)
  • Fever
  • Diarrhea
  • Constipation

Your healthcare team will monitor you closely for side effects and can help manage them if they occur[8].

Effectiveness of Decitabine

Clinical trials have shown that decitabine can be effective in treating MDS, CMML, and AML in some patients. Effectiveness is often measured by:

  • Overall response rate: The percentage of patients whose disease improves with treatment[8]
  • Complete remission: When there are no detectable signs of the disease after treatment[8]
  • Improved blood cell counts: Increases in healthy red blood cells, white blood cells, or platelets[5]
  • Transfusion independence: When patients no longer need blood or platelet transfusions[8]
  • Overall survival: How long patients live after starting treatment[8]

The effectiveness can vary depending on the specific condition and individual patient factors.

Ongoing Research and Future Directions

Researchers continue to study decitabine to find new ways to use it and improve its effectiveness. Some areas of ongoing research include:

  • Combining decitabine with other drugs to enhance its effects[2]
  • Using decitabine in new types of cancers, such as pancreatic cancer[6]
  • Developing new ways to administer the drug, such as the oral form (ASTX727)[8]
  • Studying how decitabine affects specific genetic markers in cancer cells to predict which patients might benefit most from the treatment[6]

These ongoing studies may lead to new and improved treatments for blood disorders and cancers in the future.

Aspect Details
Drug Name Decitabine (Dacogen)
Main Indications Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
Mechanism of Action Blocks DNA methylation, affecting gene expression and cell growth
Common Administration Intravenous infusion, typically 20 mg/m² over 1 hour for 5-10 days in 28-day cycles
New Formulations Oral tablets, subcutaneous injections being studied
Key Outcomes Measured Complete remission rates, overall survival, progression-free survival, pharmacokinetics, safety/adverse events
Emerging Applications Maintenance therapy, combination treatments, HPV-induced cancers, pancreatic cancer
Patient Populations Often focused on elderly patients or those unable to tolerate intensive chemotherapy

FAQ

  • What is decitabine and how does it work? Decitabine (Dacogen) is a drug that blocks DNA methylation, a process that affects gene usage in cells. It is used to treat certain blood cancers by helping to normalize cell growth and development in the bone marrow.
  • What types of cancer is decitabine being studied for? Decitabine is being investigated for various blood cancers, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and other myeloid malignancies.
  • How is decitabine typically administered? Decitabine is usually given as an intravenous (IV) infusion, often over 1 hour. Some trials are exploring oral formulations or subcutaneous injections. Common dosing schedules include daily administration for 5-10 days in 28-day cycles.
  • What are some potential side effects of decitabine? Common side effects may include low blood cell counts (which can increase risk of infection, bleeding, or fatigue), nausea, and fever. Trials are monitoring for various adverse events to better understand the drug's safety profile.
  • Are there any new ways decitabine is being studied? Yes, researchers are exploring decitabine as maintenance therapy after other treatments, in combination with other drugs, in new dosing schedules, and for additional types of cancer like HPV-induced head and neck cancers and pancreatic cancer.

Ongoing Clinical Trials on Decitabine

  • Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Germany Italy Lithuania Portugal Romania +1

  • Study of azacitidine combined with low-dose venetoclax treatment for patients with acute myeloid leukemia

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Finland Norway Sweden

  • Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Germany Hungary Poland Romania +2

  • Study of Nivolumab, Ipilimumab, and ASTX727 for Melanoma and Lung Cancer Patients Resistant to Anti-PD-1/PD-L1 Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Venetoclax and Decitabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on the Safety and Effectiveness of IMA402, Tocilizumab, and Human Serum Albumin for Patients with Recurrent or Resistant Solid Tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Germany The Netherlands

  • A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness of NMS-01940153E, Atezolizumab, and Decitabine in Adults with Unresectable Liver Cancer Previously Treated with Other Cancer Medicines

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Spain

  • Study of Venetoclax and Decitabine for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Eligible for Stem Cell Transplant

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Myelodysplastic Syndrome (MDS): A group of blood disorders where the bone marrow doesn't produce enough healthy blood cells. It can sometimes progress to acute myeloid leukemia.
  • Acute Myeloid Leukemia (AML): A type of blood cancer where the bone marrow makes abnormal myeloid cells that don't mature properly and multiply too quickly.
  • Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer that affects myeloid cells, with features of both myelodysplastic syndromes and myeloproliferative neoplasms.
  • DNA Methylation: A process that can modify DNA, affecting how genes are expressed. Abnormal methylation is common in some cancers.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Complete Remission (CR): A treatment response where all signs of cancer have disappeared, though some cancer cells may still be present in the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. https://clinicaltrials.gov/study/NCT02214407
  2. https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-decitabine-and-venetoclax-for-patients-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/
  3. https://clinicaltrials.gov/study/NCT00067808
  4. https://clinicaltrials.gov/study/NCT04252248
  5. https://clinicaltrials.gov/study/NCT00630994
  6. https://clinicaltrials.gov/study/NCT05360264
  7. https://clinicaltrials.gov/study/NCT00941109
  8. https://clinicaltrials.gov/study/NCT03306264
  9. https://clinicaltrials.gov/study/NCT01378416
  10. https://clinicaltrials.gov/study/NCT00619099